Downsizing could cause FDA to miss PDUFA goals

Current and former FDA officials warn that Trump administration personnel policies could cripple the agency’s ability to meet user fee goals for drug reviews and compromise its ability to keep pace with scientific advances.

There is a great deal of uncertainty about the effects of specific elements of the administration’s efforts to sharply and rapidly reduce the size of the federal workforce. Those ringing alarms argue that there is little doubt that, unless mitigating actions are taken soon, some of the policies will lead to departures of critical staff at FDA.  ...